A Study to Evaluate the Safety and Efficacy of PLM60 in Advanced HCC

Inclusion Criteria:

* Signed informed consent from the patient；
* ECOG performance status of 0 or 1;
* Histologically/cytologically confirmed diagnosis of advanced HCC;
* Adequate washout period for previous anti-tumor therapy;
* Measurable disease according to RECIST v1.1;
* Life expectancy ≥ 12 weeks;
* Adequate organ function;
* Child-Pugh grade A or partial grade B; BCLC stage B or C;V

Exclusion Criteria:

* Prior treatment with Mitoxantrone or Liposome-entrapped Mitoxantrone, or other anthracyclines, with the total cumulative dose of \> 360 mg/m2 ;
* Any drug-related adverse event derived from any previous anti-tumor treatment, excluding alopecia, Pigmentation, or other toxicity with little safety risk for subjects, that has not recovered to grade1 or less;
* Active central nervous system (CNS) metastases (brain or leptomeningeal metastases, etc.);
* Any history of other malignancy within 5 years;
* Untreated hepatitis infection;
* HIV positive;
* History of liver transplantation, severe cirrhosis, hepatic encephalopathy;
* Inadequate cardiac function;
* Pregnant or lactating women.